0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CA125

CA125

Brief Information

Name:Mucin-16
Target Synonym:Mucin-16 Short Isoform,Mucin-16 Long Isoform,Ovarian carcinoma antigen CA125,Ovarian cancer-related tumor marker CA125,MUC16,MUC-16,CA-125,Mucin 16, Cell Surface Associated,CA125,CA125 Ovarian Cancer Antigen,Mucin-16,CA-125 Antigen,FLJ14303
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:2
Lastest Research Phase:Phase 3 Clinical

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
CA5-H82F8 Human Biotinylated Human CA125 / MUC16 (13810-14451) Protein, Fc,Avitag™
CA5-H82F8-structure
CA5-H82F8-sds
CA5-H82F4 Human Biotinylated Human CA125 / MUC16 Protein, Fc,Avitag™
CA5-H82F4-structure
CA5-H82F4-sds
CA5-H82F4-elisa_1

Part of Bioactivity data

CA5-H82F4-ELISA
Biotinylated Human CA125, Fc,AvitagBiotinylated Human CA125, Fc,Avitag (Cat. No. CA5-H82F4) ELISA bioactivity

Immobilized Human Mesothelin, His Tag (Cat. No. MSN-H5223) at 10 μg/mL (100 μL/well) can bind Biotinylated Human CA125, Fc,Avitag (Cat. No. CA5-H82F4) with a linear range of 2-78 ng/mL (QC tested).

Synonym Name

CA125, CA-125, CA125MUC-16, FLJ14303, MUC16, mucin 16, mucin-16

Background

The CA125, also known as the MUC16, is a mucin protein that may be found in type I transmembrane or secreted forms that are used monitor the progress of epithelial ovarian cancer therapy. The CA 125 molecule is almost certainly a glycoprotein with a predominance of O-linkages. It is heterogeneous with regard to both size and charge, most likely due to continuous deglycosylation of side chains during its life-span in bodily fluids. It exists as a very large complex (perhaps as much as 4 million daltons) under natural conditions.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
JCAR-020 JCAR-020 Phase 1 Clinical Memorial Sloan Kettering Cancer Center Ovarian Neoplasms Details
Oregovomab B43.13 Phase 3 Clinical Paladin Pharma Ovarian Neoplasms; Carcinoma; Abdominal Neoplasms; Carcinoma, Ovarian Epithelial; Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Adenocarcinoma Details

This web search service is supported by Google Inc.

totop